Literature DB >> 24147812

A de novo novel cardiac ryanodine mutation (Ser4155Tyr) associated with catecholaminergic polymorphic ventricular tachycardia.

Lilian Mantziari1, Vassilios Vassilikos, Aris Anastasakis, Xanthippi Kotsaka, Stelios Paraskevaidis, Ioannis H Styliadis, David Luria.   

Abstract

We describe the case of a 14-year-old girl with a history of syncopal episodes triggered by stress or exercise. Catecholaminergic polymorphic ventricular tachycardia was diagnosed with the aid of an implantable loop recorder. The genetic testing of the patient and her family revealed a de novo novel missense mutation (Ser4155Tyr) in the exon 90 of the ryanodine receptor gene. This mutation affects a highly conserved residue (S4155) and results to replacement of serine (S) with tyrosine (Y) leading to change in physical and chemical properties. The girl was treated with an implantable defibrillator, metoprolol and flecainide. Over 1 year of follow-up she had no recurrence of ventricular tachycardia. ©2013 Wiley Periodicals, Inc.

Entities:  

Keywords:  basic, electrophysiology-cardiac arrest/sudden death; clinical; clinical, electrophysiology-ventricular tachycardia; clinical, implantable devices-ventricular tachycardia/fibrillation; clinical, pediatrics-implantable devices; molecular biology/genetics

Mesh:

Substances:

Year:  2013        PMID: 24147812      PMCID: PMC6932309          DOI: 10.1111/anec.12089

Source DB:  PubMed          Journal:  Ann Noninvasive Electrocardiol        ISSN: 1082-720X            Impact factor:   1.468


  3 in total

1.  Arrhythmia characterization and long-term outcomes in catecholaminergic polymorphic ventricular tachycardia.

Authors:  Raymond W Sy; Michael H Gollob; George J Klein; Raymond Yee; Allan C Skanes; Lorne J Gula; Peter Leong-Sit; Robert M Gow; Martin S Green; David H Birnie; Andrew D Krahn
Journal:  Heart Rhythm       Date:  2011-02-09       Impact factor: 6.343

2.  Mechanism underlying catecholaminergic polymorphic ventricular tachycardia and approaches to therapy.

Authors:  Hiroshi Watanabe; Björn C Knollmann
Journal:  J Electrocardiol       Date:  2011-08-27       Impact factor: 1.438

3.  The RYR2-encoded ryanodine receptor/calcium release channel in patients diagnosed previously with either catecholaminergic polymorphic ventricular tachycardia or genotype negative, exercise-induced long QT syndrome: a comprehensive open reading frame mutational analysis.

Authors:  Argelia Medeiros-Domingo; Zahurul A Bhuiyan; David J Tester; Nynke Hofman; Hennie Bikker; J Peter van Tintelen; Marcel M A M Mannens; Arthur A M Wilde; Michael J Ackerman
Journal:  J Am Coll Cardiol       Date:  2009-11-24       Impact factor: 24.094

  3 in total
  3 in total

1.  The Role of Flecainide in the Management of Catecholaminergic Polymorphic Ventricular Tachycardia.

Authors:  Krystien Vv Lieve; Arthur A Wilde; Christian van der Werf
Journal:  Arrhythm Electrophysiol Rev       Date:  2016-05

Review 2.  Multiple targets for flecainide action: implications for cardiac arrhythmogenesis.

Authors:  Samantha C Salvage; Karthik H Chandrasekharan; Kamalan Jeevaratnam; Angela F Dulhunty; Andrew J Thompson; Antony P Jackson; Christopher L-H Huang
Journal:  Br J Pharmacol       Date:  2017-05-12       Impact factor: 8.739

3.  Pooled Analysis of Complications with Transvenous ICD Compared to Subcutaneous ICD in Patients with Catecholaminergic Polymorphic Ventricular Arrhythmia.

Authors:  Henrik Eckert; Ibrahim El-Battrawy; Michael Veith; Gretje Roterberg; Jacqueline Kowitz; Siegfried Lang; Xiaobo Zhou; Ibrahim Akin; Andreas Mügge; Assem Aweimer
Journal:  J Pers Med       Date:  2022-03-28
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.